(E)-N-(4-(3-(3,4-dihydroxyphenyl)acryloyl)phenyl)-3,4-difluorobenzamide | 1273524-60-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-N-(4-(3-(3,4-dihydroxyphenyl)acryloyl)phenyl)-3,4-difluorobenzamide
• 英文别名: N-[4-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]phenyl]-3,4-difluorobenzamide
• CAS: 1273524-60-9
• 化学式: C₂₂H₁₅F₂NO₄
• 分子量: 395.362
• InChiKey: XWDNEVSNPWFQLF-XLUWADSXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氨基苯乙酮 在 甲烷磺酸 作用下， 以 四氢呋喃 为溶剂， 反应 4.08h， 生成 (E)-N-(4-(3-(3,4-dihydroxyphenyl)acryloyl)phenyl)-3,4-difluorobenzamide
  参考文献：
  名称：

  Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5

  摘要：

  Designing multi-functional ligands is a recent strategy by which multiple targets can be inhibited by a single entity. A series of caffeoyl-anilide compounds based on structures of various integrase and CCR5 inhibitors have been designed and synthesized as anti-HIV agents in the present study. Most of the compounds exhibited potent anti-HIV activity at micromolar concentration in CEM-GFP CD4+ T cells infected with HIV-1NL4.3 virus. Compound 14 showed a lower EC50 and better TI as compared to AZT. Mechanism based studies suggest that these compounds inhibit either one or in some cases, both the targets. The experimental data and the docking results showed that these compounds are potential inhibitors for both HIV-1 IN and CCR5. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.031

文献信息

• Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5
  作者：Hardik S. Bodiwala、Sudeep Sabde、Pawan Gupta、Ruchira Mukherjee、Rajender Kumar、Prabha Garg、Kamlesh Kumar Bhutani、Debashis Mitra、Inder Pal Singh

  DOI：10.1016/j.bmc.2010.12.031

  日期：2011.2

  Designing multi-functional ligands is a recent strategy by which multiple targets can be inhibited by a single entity. A series of caffeoyl-anilide compounds based on structures of various integrase and CCR5 inhibitors have been designed and synthesized as anti-HIV agents in the present study. Most of the compounds exhibited potent anti-HIV activity at micromolar concentration in CEM-GFP CD4+ T cells infected with HIV-1NL4.3 virus. Compound 14 showed a lower EC50 and better TI as compared to AZT. Mechanism based studies suggest that these compounds inhibit either one or in some cases, both the targets. The experimental data and the docking results showed that these compounds are potential inhibitors for both HIV-1 IN and CCR5. (C) 2010 Elsevier Ltd. All rights reserved.